NOVN.SW Novartis (SIX) CHF115.90 intraday 02 Feb 2026: Earnings 04 Feb could guide next move

The NOVN.SW stock trades at CHF115.90 intraday on 02 Feb 2026 as investors position ahead of Novartis earnings on 04 Feb 2026. The share is up 1.42% today on volume of 577,433 against an average of 2,932,056. Key fundamentals show EPS 5.58 and PE 20.54, with market cap CHF219.93B on the SIX exchange in Switzerland. This earnings spotlight examines drivers, risks, and short-term price signals that could shape the stock after the report.

NOVN.SW stock: intraday price action and liquidity

Novartis shares opened at CHF114.76 and hit a day high of CHF115.90. Volume of 577,433 equals a relative volume of 1.08, so trading is active but below the 50-day average. The 50-day average price is CHF109.88, and the 200-day average is CHF100.93, showing a clear upward trend over recent months.

NOVN.SW stock: fundamentals ahead of earnings

Novartis reports EPS 5.58 and a PE of 20.54, consistent with large healthcare peers. Revenue per share is 28.94 and free cash flow per share is 9.39, supporting the dividend and buyback optionality. The company trades on SIX in Switzerland with year high CHF117.14 and year low CHF81.10, highlighting multi-month strength.

NOVN.SW stock: Meyka grade and model forecast

Meyka AI rates NOVN.SW with a score out of 100: 74.39 (Grade B+, Suggestion: BUY). This grade factors S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly CHF123.14, implying an upside of +6.25% versus current CHF115.90. Forecasts are model-based projections and not guarantees.

NOVN.SW stock: technicals and near-term signals

Momentum indicators show near-term strength with RSI 74.23 and MACD histogram 0.53, signaling short-term overbought conditions. Price sits above the Bollinger middle band CHF108.81, supporting trend continuation if earnings meet expectations. Traders should watch ATR 1.69 for intraday risk and OBV for flow confirmation.

NOVN.SW stock: earnings catalysts, risks and sector context

Key catalysts include core Innovative Medicines sales, Sandoz margin progress, and progress on inclisiran partnerships. Risks include pricing pressure, generic competition, and execution at Sandoz. The Swiss healthcare sector has a 1Y average PE near 34.55, so Novartis trades relatively cheaper on PE 20.54, though PB is elevated at 6.52.

NOVN.SW stock: short-term price targets and trading strategy

Given fundamentals and technicals, a near-term target is CHF125.00 and a 12-month target is CHF135.00. Defensive traders may use a stop below CHF114.72 intraday low. Active traders can watch a breakout above CHF117.14 to confirm continuation and a miss below CHF109.88 to signal consolidation.

Final Thoughts

We see NOVN.SW stock trading at CHF115.90 with earnings due on 04 Feb 2026 providing the next major catalyst. Fundamentals show EPS 5.58, PE 20.54, and solid cash flow per share 9.39, which supports dividends and strategic investments. Technically, the price sits above both the 50-day and 200-day averages, but RSI at 74.23 warns of short-term overbought conditions. Meyka AI’s model projects CHF123.14 monthly, implying +6.25% upside from current levels. Use earnings as a clearing event. If results beat on growth and margins, the CHF125.00–CHF135.00 range is a reasonable near-term target. If results disappoint, watch support near CHF109.88. These figures are analysis, not trading advice. Meyka AI is an AI-powered market analysis platform and our forecasts are model-based projections, not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.